BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug
BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.
BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.
What's Your Reaction?
